Elanco Animal Health Inc - Company Profile
Powered by 
All the sales intelligence you need on Elanco Animal Health Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Elanco Animal Health Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Elanco Animal Health Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Elanco Animal Health Inc (Elanco) is a provider of animal health products. The company's primary activities involve innovating and delivering products and services to prevent and treat diseases in farm animals and pets. Its product portfolio includes parasiticides, injectable antibiotics, vaccines, therapeutics, medicated feed activities, insecticides and enzymes, among others. Elanco's product portfolio is diverse, catering to a variety of species including dogs, poultry, cats, cattle, swine and sheep. The company’s customers include farmers, pet owners, and veterinarians. The company markets its brands under the brand names advantage, k-9 advantix, credelio plus, interceptor plus, Advocate, adtab, Credelio, TruCan, Trutect, Credelio Cat and Drontal. The company markets its products across Asia, Europe, Australia, North America and the Middle East. Elanco is headquartered in Greenfield, Indiana, the US.
Headquarters
United States of America
Address
450 Elanco Circle, Indianapolis, 46221
Website
www.elanco.com
Telephone
1 877 3526261
No of Employees
9,400
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ELAN (NYSE)
Revenue (2024)
$4.7B
6.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-168.6%
(2024 vs 2023)
Market Cap*
$12.3B
Net Profit Margin (2024)
XYZ
-164.7%
(2024 vs 2023)
* As of and is in US$
Elanco Animal Health Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | Advantage |
| Parasiticides | Nutritional Services | K-9 Advantix |
| Vaccines | Data Analytics | Advocate |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company secured approval from U.S. Department of Agriculture for TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. |
| 2026 | Plans/Strategy | In June, the company announced plans to launch Elanco Ventures, a corporate venture capital platform. |
| 2026 | New Products/Services | In May, the company launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injection. |
Competitor Comparison
| Key Parameters | Elanco Animal Health Inc | Zoetis Inc | Virbac SA | Ceva Sante Animale SA | Boehringer Ingelheim Animal Health Gmbh |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | France | Germany |
| City | Indianapolis | Parsippany | Carros | Libourne | Ingelheim Am Rhein |
| State/Province | Indiana | New Jersey | Provence - Alpes- Cote d'Azur | Aquitaine | Rheinland-Pfalz |
| No. of Employees | 9,400 | 14,500 | 6,442 | 7,000 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lawrence E. Kurzius | Chairman | Executive Board | 2018 | 68 |
| Jeffrey N. Simmons | President; Director; Chief Executive Officer | Executive Board | 2018 | 58 |
| Robert VanHimbergen | Chief Financial Officer; Executive Vice President | Senior Management | 2025 | 49 |
| Tim Bettington | Executive Vice President - Center of Strategic Growt | Senior Management | 2023 | 52 |
| Rajeev Modi | Executive Vice President - U.S. Pet Health and Global Digital Transformation. | Senior Management | 2022 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer